PA5-51640

antibody from Invitrogen Antibodies

Targeting: CFB BF, BFD, H2-Bf

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-51640

Provider

Invitrogen Antibodies

Product name

Complement Factor B Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Immunogen sequence: KDNEQHVFKV KDMENLEDVF YQMIDESQSL SLCGMVWEHR KGTDYHKQPW QAKISVIRPS KGHESCMGAV VSEYFVLTAA HCFTVDDKEH SIKVSVGGEK RDLEIEVVLF HPNYNINGKK EAGIPEFYDY DVALIKLKNK LKYG Highest antigen sequence identity to the following orthologs: Mouse - 86%, Rat - 81%.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

0.08 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Challenge of Bovine Foot Skin Fibroblasts With Digital Dermatitis Treponemes Identifies Distinct Pathogenic Mechanisms.

Newbrook K, Carter SD, Crosby-Durrani H, Evans NJ
Frontiers in cellular and infection microbiology 2020;10:538591

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent staining of Complement Factor B in human cell line ASC TERT1 using Complement Factor B Polyclonal Antibody (Product # PA5-51640) shows localization to endoplasmic reticulum.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 7 Immunohistochemistry (IHC) of CFB and RND1 on bovine foot skin from the site of BDD lesions. Low power images accompanied with high power inserts. Images shown are representatives of three independent experimental replicates (n = 3) for each tissue lesion type (no BDD, acute BDD, chronic BDD). (A-C) IHC for CFB. (A) No BDD. Labeling of lymphocytes and plasma cells at the dermal-epidermal junction (x20), with insert confirming identification of labeled mononuclear cells (x100). (B) Acute BDD. Intense labeling of the most superficial keratinocytes (x20), with insert showing intense cytoplasmic and membranous labeling of the most superficial keratinocytes (xx400). (C) Chronic BDD lesion (x20, x400) exhibiting similar findings to (B) . (D-F) IHC for RND1. (D) No BDD. Multifocally, the stratum corneum has granular background labeling of the stratum corneum keratinocytes (x20, x100). (E) Acute BDD. Multifocally, there are intensely labeled keratinocytes near to ulcerated regions (x20), with insert highlighting view of intense labeling (x400). (F) Chronic BDD. Multifocal mild granular labeling of the stratum corneum keratinocytes similar to (D) ; however, note most of the thickened stratum corneum is not labeled (20). Insert shows background labeling of some stratum corneum keratinocytes (400).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 8 Immunohistochemistry (IHC) of IL-6 on bovine foot skin tissue from the site of BDD lesions. Low power images accompanied with high power inserts. Images shown are representatives of three independent experimental replicates (n = 3) for each tissue lesion type (no BDD, acute BDD, chronic BDD). (A-C) IHC for IL-6. (A) No BDD. Lymphocytes and plasma cells at the dermal-epidermal junction are intensely labelled (x20, x100). (B) Acute BDD. Positive labeling of the stratum corneum and some stratum spinosum keratinocytes (x40), with insert showing intense labeling of spirochaetal structures (x400). Arrow denotes labeling showing similar morphology and location to that observed with DD treponeme IHC ( Figure S4E ) (C) Chronic BDD lesion (x20, x400) exhibiting similar findings to (B) . Arrow denotes labeling showing similar morphology and location to that observed with DD treponeme IHC ( Figure S4F ). (D-E) IL-6 negative antibody (no primary antibody) control. (D) Acute BDD (x20, x400). (E) Chronic BDD (x20, x400).